Cargando…
Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo
Clostridioides difficile is a leading cause of antibiotic-associated diarrhea and nosocomial infection in the United States. The symptoms of C. difficile infection (CDI) are associated with the production of two homologous protein toxins, TcdA and TcdB. The toxins are considered bona fide targets fo...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621975/ https://www.ncbi.nlm.nih.gov/pubmed/37871122 http://dx.doi.org/10.1371/journal.ppat.1011496 |
_version_ | 1785130469444026368 |
---|---|
author | Kordus, Shannon L. Kroh, Heather K. Rodríguez, Rubén Cano Shrem, Rebecca A. Peritore-Galve, F. Christopher Shupe, John A. Wadzinski, Brian E. Lacy, D. Borden Spiller, Benjamin W. |
author_facet | Kordus, Shannon L. Kroh, Heather K. Rodríguez, Rubén Cano Shrem, Rebecca A. Peritore-Galve, F. Christopher Shupe, John A. Wadzinski, Brian E. Lacy, D. Borden Spiller, Benjamin W. |
author_sort | Kordus, Shannon L. |
collection | PubMed |
description | Clostridioides difficile is a leading cause of antibiotic-associated diarrhea and nosocomial infection in the United States. The symptoms of C. difficile infection (CDI) are associated with the production of two homologous protein toxins, TcdA and TcdB. The toxins are considered bona fide targets for clinical diagnosis as well as the development of novel prevention and therapeutic strategies. While there are extensive studies that document these efforts, there are several gaps in knowledge that could benefit from the creation of new research tools. First, we now appreciate that while TcdA sequences are conserved, TcdB sequences can vary across the span of circulating clinical isolates. An understanding of the TcdA and TcdB epitopes that drive broadly neutralizing antibody responses could advance the effort to identify safe and effective toxin-protein chimeras and fragments for vaccine development. Further, an understanding of TcdA and TcdB concentration changes in vivo can guide research into how host and microbiome-focused interventions affect the virulence potential of C. difficile. We have developed a panel of alpaca-derived nanobodies that bind specific structural and functional domains of TcdA and TcdB. We note that many of the potent neutralizers of TcdA bind epitopes within the delivery domain, a finding that could reflect roles of the delivery domain in receptor binding and/or the conserved role of pore-formation in the delivery of the toxin enzyme domains to the cytosol. In contrast, neutralizing epitopes for TcdB were found in multiple domains. The nanobodies were also used for the creation of sandwich ELISA assays that allow for quantitation of TcdA and/or TcdB in vitro and in the cecal and fecal contents of infected mice. We anticipate these reagents and assays will allow researchers to monitor the dynamics of TcdA and TcdB production over time, and the impact of various experimental interventions on toxin production in vivo. |
format | Online Article Text |
id | pubmed-10621975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-106219752023-11-03 Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo Kordus, Shannon L. Kroh, Heather K. Rodríguez, Rubén Cano Shrem, Rebecca A. Peritore-Galve, F. Christopher Shupe, John A. Wadzinski, Brian E. Lacy, D. Borden Spiller, Benjamin W. PLoS Pathog Research Article Clostridioides difficile is a leading cause of antibiotic-associated diarrhea and nosocomial infection in the United States. The symptoms of C. difficile infection (CDI) are associated with the production of two homologous protein toxins, TcdA and TcdB. The toxins are considered bona fide targets for clinical diagnosis as well as the development of novel prevention and therapeutic strategies. While there are extensive studies that document these efforts, there are several gaps in knowledge that could benefit from the creation of new research tools. First, we now appreciate that while TcdA sequences are conserved, TcdB sequences can vary across the span of circulating clinical isolates. An understanding of the TcdA and TcdB epitopes that drive broadly neutralizing antibody responses could advance the effort to identify safe and effective toxin-protein chimeras and fragments for vaccine development. Further, an understanding of TcdA and TcdB concentration changes in vivo can guide research into how host and microbiome-focused interventions affect the virulence potential of C. difficile. We have developed a panel of alpaca-derived nanobodies that bind specific structural and functional domains of TcdA and TcdB. We note that many of the potent neutralizers of TcdA bind epitopes within the delivery domain, a finding that could reflect roles of the delivery domain in receptor binding and/or the conserved role of pore-formation in the delivery of the toxin enzyme domains to the cytosol. In contrast, neutralizing epitopes for TcdB were found in multiple domains. The nanobodies were also used for the creation of sandwich ELISA assays that allow for quantitation of TcdA and/or TcdB in vitro and in the cecal and fecal contents of infected mice. We anticipate these reagents and assays will allow researchers to monitor the dynamics of TcdA and TcdB production over time, and the impact of various experimental interventions on toxin production in vivo. Public Library of Science 2023-10-23 /pmc/articles/PMC10621975/ /pubmed/37871122 http://dx.doi.org/10.1371/journal.ppat.1011496 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Kordus, Shannon L. Kroh, Heather K. Rodríguez, Rubén Cano Shrem, Rebecca A. Peritore-Galve, F. Christopher Shupe, John A. Wadzinski, Brian E. Lacy, D. Borden Spiller, Benjamin W. Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo |
title | Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo |
title_full | Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo |
title_fullStr | Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo |
title_full_unstemmed | Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo |
title_short | Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo |
title_sort | nanobodies against c. difficile tcda and tcdb reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621975/ https://www.ncbi.nlm.nih.gov/pubmed/37871122 http://dx.doi.org/10.1371/journal.ppat.1011496 |
work_keys_str_mv | AT kordusshannonl nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo AT krohheatherk nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo AT rodriguezrubencano nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo AT shremrebeccaa nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo AT peritoregalvefchristopher nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo AT shupejohna nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo AT wadzinskibriane nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo AT lacydborden nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo AT spillerbenjaminw nanobodiesagainstcdifficiletcdaandtcdbrevealunexpectedneutralizingepitopesandprovideatoolkitfortoxinquantitationinvivo |